Literature DB >> 18633024

The relationship between patient risk factors and early versus late postoperative emetic symptoms.

Paul F White1, Ozlem Sacan, Nina Nuangchamnong, Tiffany Sun, Matthew R Eng.   

Abstract

BACKGROUND: Postoperative nausea and vomiting (PONV) remain common complications after elective surgery. Prophylactic antiemetic drugs are frequently administered to patients with well known risk factors for developing PONV. We designed this prospective observational study to assess the relationship between common patient risk factors for developing PONV and the occurrence of early (0-24 h) versus late (24-72 h) emetic symptoms.
METHODS: One hundred thirty patients undergoing elective laparoscopic (n = 88) or plastic (n = 42) surgery were assigned a risk score for developing PONV based on the Apfel risk scoring system, which assigns one point each for female gender, nonsmoking status, history of PONV or motion sickness, and postoperative opioid use. It was assumed that all patients would receive an opioid analgesic in the postoperative period. The patients received 0, 1, 2, or 3 antiemetic drugs for prophylaxis. The occurrence of nausea, vomiting, and need for rescue antiemetics was assessed at specific time intervals from 0 to 6, 6-24, and 24-72 h after surgery. In addition, the impact of PONV on recovery of normal activities of daily living was assessed using a standardized patient questionnaire.
RESULTS: One or more prophylactic antiemetics were administered to 87%, 90%, and 95% of the patients in the two, three, and four Apfel risk-factor groups, respectively. In the presence of three or four risk factors, >/=2 antiemetics were administered to 56% and 75% of the patients, respectively. Vomiting was reported in 11% and 22% of patients in the three and four risk factor groups compared with 6% in the two risk factor group at 0-6 h, and 13% and 27% (vs 0%) at 6-24 h, respectively. However, in the 24-72 h postoperative period, the incidences of emesis were low and did not differ in the three risk groups (9%, 5%, and 11%, respectively). The occurrence of moderate-to-severe nausea was increased in the higher risk groups at 0-6 h and 6-24 h (19%-28% vs 6% and 20%-30% vs 9%, respectively). However, the incidences of nausea in the 24-72 h period in the three and four risk factor groups were not different from the two-risk factor group (5% and 8% vs 6%, respectively). The need for rescue antiemetics and interference of emetic symptoms with normal activities was greater in the four risk factor group compared with the two and three risk factor groups.
CONCLUSION: Despite the frequent use of multiple antiemetic drugs for prophylaxis, an Apfel risk score of three or four (vs 2) was associated with a higher incidence of emetic sequelae in the first 24 h after surgery. However, the occurrence of late (24-72 h) emetic symptoms was low and appeared to be unrelated to the patient's Apfel risk score.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18633024     DOI: 10.1213/ane.0b013e31817aa6e4

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  12 in total

Review 1.  Perioperative Care of Elderly Surgical Outpatients.

Authors:  Xuezhao Cao; Paul F White; Hong Ma
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 3.923

2.  A prospective, randomized, controlled trial of the postoperative analgesic effects of spraying 0.25 % levobupivacaine after bilateral axillo-breast approach robotic thyroidectomy.

Authors:  Jung-Hee Ryu; Cha Kyong Yom; Hyungju Kwon; Kyu Hyung Kim; June Young Choi; Jun Woo Jung; Sung-Won Kim; Ah-Young Oh
Journal:  Surg Endosc       Date:  2014-08-14       Impact factor: 4.584

3.  Incidence and risk factors of postoperative nausea and vomiting in patients with fentanyl-based intravenous patient-controlled analgesia and single antiemetic prophylaxis.

Authors:  Jong Bum Choi; Yon Hee Shim; Youn-Woo Lee; Jeong Soo Lee; Jong-Rim Choi; Chul Ho Chang
Journal:  Yonsei Med J       Date:  2014-09       Impact factor: 2.759

4.  A Prospective Study of Nausea and Vomiting After Breast Cancer Surgery.

Authors:  Susan W Wesmiller; Catherine M Bender; Yvette P Conley; Dana H Bovbjerg; Gretchen Ahrendt; Marguerite Bonaventura; Susan M Sereika
Journal:  J Perianesth Nurs       Date:  2016-09-01       Impact factor: 1.084

Review 5.  An update on the management of postoperative nausea and vomiting.

Authors:  Xuezhao Cao; Paul F White; Hong Ma
Journal:  J Anesth       Date:  2017-04-28       Impact factor: 2.078

Review 6.  Postoperative Nausea and Vomiting in Female Patients Undergoing Breast and Gynecological Surgery: A Narrative Review of Risk Factors and Prophylaxis.

Authors:  Marco Echeverria-Villalobos; Juan Fiorda-Diaz; Alberto Uribe; Sergio D Bergese
Journal:  Front Med (Lausanne)       Date:  2022-07-01

7.  Paracetamol reduces postoperative pain and rescue analgesic demand after robot-assisted endoscopic thyroidectomy by the transaxillary approach.

Authors:  Jeong-Yeon Hong; Won Oak Kim; Woong Youn Chung; Joo Sun Yun; Hae Keum Kil
Journal:  World J Surg       Date:  2010-03       Impact factor: 3.352

8.  Comparison of palanosetron with ondansetron for postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy under general anesthesia.

Authors:  Jyoti Bhalla; Neha Baduni; Pooja Bansal
Journal:  J Minim Access Surg       Date:  2015 Jul-Sep       Impact factor: 1.407

9.  Gender-Specific Differences in Low-Dose Haloperidol Response for Prevention of Postoperative Nausea and Vomiting: A Register-Based Cohort Study.

Authors:  Florian Brettner; Silke Janitza; Kathrin Prüll; Ernst Weninger; Ulrich Mansmann; Helmut Küchenhoff; Alexander Jovanovic; Bernhard Pollwein; Daniel Chappell; Bernhard Zwissler; Vera von Dossow
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

10.  Management of postoperative nausea and vomiting: focus on palonosetron.

Authors:  Neil A Muchatuta; Michael J Paech
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.